502 related articles for article (PubMed ID: 27345129)
1. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.
Al-Hallaq HA; Chmura S; Salama JK; Winter KA; Robinson CG; Pisansky TM; Borges V; Lowenstein JR; McNulty S; Galvin JM; Followill DS; Timmerman RD; White JR; Xiao Y; Matuszak MM
Pract Radiat Oncol; 2016; 6(6):e291-e298. PubMed ID: 27345129
[TBL] [Abstract][Full Text] [Related]
2. Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases.
Al-Hallaq HA; Chmura SJ; Salama JK; Lowenstein JR; McNulty S; Galvin JM; Followill DS; Robinson CG; Pisansky TM; Winter KA; White JR; Xiao Y; Matuszak MM
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):155-163. PubMed ID: 27843033
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.
Chmura S; Winter KA; Robinson C; Pisansky TM; Borges V; Al-Hallaq H; Matuszak M; Park SS; Yi S; Hasan Y; Bazan J; Wong P; Yoon HA; Horton J; Gan G; Milano MT; Sigurdson ER; Moughan J; Salama JK; White J
JAMA Oncol; 2021 Jun; 7(6):845-852. PubMed ID: 33885704
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
[TBL] [Abstract][Full Text] [Related]
5. Functional image-guided stereotactic body radiation therapy planning for patients with hepatocellular carcinoma.
Tsegmed U; Kimura T; Nakashima T; Nakamura Y; Higaki T; Imano N; Doi Y; Kenjo M; Ozawa S; Murakami Y; Awai K; Nagata Y
Med Dosim; 2017 Summer; 42(2):97-103. PubMed ID: 28433483
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT).
Xiao A; Luke JJ; Partouche J; Karrison T; Chmura SJ; Al-Hallaq HA
Pract Radiat Oncol; 2022; 12(1):68-77. PubMed ID: 34607037
[TBL] [Abstract][Full Text] [Related]
7. Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.
Moustakis C; Blanck O; Ebrahimi Tazehmahalleh F; Ka Heng Chan M; Ernst I; Krieger T; Duma MN; Oechsner M; Ganswindt U; Heinz C; Alheit H; Blank H; Nestle U; Wiehle R; Kornhuber C; Ostheimer C; Petersen C; Pollul G; Baus W; Altenstein G; Beckers E; Jurianz K; Sterzing F; Kretschmer M; Seegenschmiedt H; Maass T; Droege S; Wolf U; Schoeffler J; Haverkamp U; Eich HT; Guckenberger M
Strahlenther Onkol; 2017 Oct; 193(10):780-790. PubMed ID: 28567503
[TBL] [Abstract][Full Text] [Related]
8. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
9. Single institution experience treating adrenal metastases with stereotactic body radiation therapy.
Shah MM; Isrow D; Fareed MM; Wen N; Ryu S; Ajlouni M; Siddiqui F
J Cancer Res Ther; 2019 Mar; 15(Supplement):S27-S32. PubMed ID: 30900616
[TBL] [Abstract][Full Text] [Related]
10. Accumulated Delivered Dose Response of Stereotactic Body Radiation Therapy for Liver Metastases.
Swaminath A; Massey C; Brierley JD; Dinniwell R; Wong R; Kim JJ; Velec M; Brock KK; Dawson LA
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):639-48. PubMed ID: 26461006
[TBL] [Abstract][Full Text] [Related]
11. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E
Christ SM; Alongi F; Ricardi U; Scorsetti M; Livi L; Balermpas P; Lievens Y; Braam P; Jereczek-Fossa BA; Stellamans K; Ratosa I; Widder J; Peulen H; Dirix P; Bral S; Ramella S; Hemmatazad H; Khanfir K; Geets X; Jeene P; Zilli T; Fournier B; Ivaldi GB; Clementel E; Fortpied C; Oppong FB; Ost P; Guckenberger M
Radiother Oncol; 2024 Jun; 195():110235. PubMed ID: 38508239
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases.
Chi A; Jang SY; Welsh JS; Nguyen NP; Ong E; Gobar L; Komaki R
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):856-62. PubMed ID: 21255942
[TBL] [Abstract][Full Text] [Related]
13. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis.
Macdonald OK; Kruse JJ; Miller JM; Garces YI; Brown PD; Miller RC; Foote RL
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):950-8. PubMed ID: 19801106
[TBL] [Abstract][Full Text] [Related]
14. Treatment of non-small cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty.
Seco J; Panahandeh HR; Westover K; Adams J; Willers H
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):354-61. PubMed ID: 21985941
[TBL] [Abstract][Full Text] [Related]
15. Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 Trial.
Heinzerling JH; Pen OV; Robinson M; Foster R; Kelly B; Mileham KF; Moeller B; Prabhu RS; Corso C; Ward MW; Sullivan CM; Burri S; Simone CB
Pract Radiat Oncol; 2023; 13(6):531-539. PubMed ID: 37406774
[TBL] [Abstract][Full Text] [Related]
16. A treatment planning comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based stereotactic body radiotherapy for central early-stage non-small cell lung cancer.
Merna C; Rwigema JC; Cao M; Wang PC; Kishan AU; Michailian A; Lamb J; Sheng K; Agazaryan N; Low DA; Kupelian P; Steinberg ML; Lee P
Med Dosim; 2016; 41(1):87-91. PubMed ID: 26755076
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric comparison of CT-guided iodine-125 seed stereotactic brachytherapy and stereotactic body radiation therapy in the treatment of NSCLC.
Li R; Zhang Y; Yuan Y; Lin Q; Dai J; Xu R; Hu X; Han M
PLoS One; 2017; 12(11):e0187390. PubMed ID: 29121047
[TBL] [Abstract][Full Text] [Related]
18. What do radiation oncologists require for future advancements in lung SBRT?
Ricardi U; Badellino S; Filippi AR
Phys Med; 2017 Dec; 44():150-156. PubMed ID: 27914779
[TBL] [Abstract][Full Text] [Related]
19. [Hepatic tumors and radiotherapy].
Rio E; Mornex F; Peiffert D; Huertas A
Cancer Radiother; 2016 Sep; 20 Suppl():S174-8. PubMed ID: 27521035
[TBL] [Abstract][Full Text] [Related]
20. A multi-institutional study to assess adherence to lung stereotactic body radiotherapy planning goals.
Woerner A; Roeske JC; Harkenrider MM; Fan J; Aydogan B; Koshy M; Laureckas R; Vali F; Campana M; Surucu M
Med Phys; 2015 Aug; 42(8):4629-35. PubMed ID: 26233190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
